PCVX Valuation

Vaxcyte Inc

Add to Watchlist

Advanced Chart

31.910

+0.65(2.079%)1D

Overview
Forecast
Valuation
Earnings

PCVX Relative Valuation

PCVX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PCVX is overvalued; if below, it's undervalued.

Historical Valuation

Vaxcyte Inc (PCVX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -12.71. The fair price of Vaxcyte Inc (PCVX) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：31.91

Fair

-5.19

Trailing

Forward

-3.33

EV/EBITDA

Vaxcyte Inc. (PCVX) has a current EV/EBITDA of -3.33. The 5-year average EV/EBITDA is -11.17. The thresholds are as follows: Strongly Undervalued below -21.95, Undervalued between -21.95 and -16.56, Fairly Valued between -5.78 and -16.56, Overvalued between -5.78 and -0.39, and Strongly Overvalued above -0.39. The current Forward EV/EBITDA of -3.33 falls within the Overvalued range.

-2.91

EV/EBIT

Vaxcyte Inc. (PCVX) has a current EV/EBIT of -2.91. The 5-year average EV/EBIT is -9.51. The thresholds are as follows: Strongly Undervalued below -18.53, Undervalued between -18.53 and -14.02, Fairly Valued between -4.99 and -14.02, Overvalued between -4.99 and -0.48, and Strongly Overvalued above -0.48. The current Forward EV/EBIT of -2.91 falls within the Overvalued range.

0.00

Vaxcyte Inc. (PCVX) has a current PS of 0.00. The 5-year average PS is 668.49. The thresholds are as follows: Strongly Undervalued below -1609.79, Undervalued between -1609.79 and -470.65, Fairly Valued between 1807.62 and -470.65, Overvalued between 1807.62 and 2946.76, and Strongly Overvalued above 2946.76. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-7.77

P/OCF

Vaxcyte Inc. (PCVX) has a current P/OCF of -7.77. The 5-year average P/OCF is -15.19. The thresholds are as follows: Strongly Undervalued below -32.21, Undervalued between -32.21 and -23.70, Fairly Valued between -6.67 and -23.70, Overvalued between -6.67 and 1.84, and Strongly Overvalued above 1.84. The current Forward P/OCF of -7.77 falls within the Historic Trend Line -Fairly Valued range.

-4.86

P/FCF

Vaxcyte Inc. (PCVX) has a current P/FCF of -4.86. The 5-year average P/FCF is -13.89. The thresholds are as follows: Strongly Undervalued below -24.95, Undervalued between -24.95 and -19.42, Fairly Valued between -8.36 and -19.42, Overvalued between -8.36 and -2.83, and Strongly Overvalued above -2.83. The current Forward P/FCF of -4.86 falls within the Overvalued range.

Vaxcyte Inc (PCVX) has a current Price-to-Book (P/B) ratio of 1.32. Compared to its 3-year average P/B ratio of 3.86 , the current P/B ratio is approximately -65.76% higher. Relative to its 5-year average P/B ratio of 3.95, the current P/B ratio is about -66.58% higher. Vaxcyte Inc (PCVX) has a Forward Free Cash Flow (FCF) yield of approximately -13.70%. Compared to its 3-year average FCF yield of -6.65%, the current FCF yield is approximately 105.89% lower. Relative to its 5-year average FCF yield of -6.62% , the current FCF yield is about 106.78% lower.

1.32

P/B

Median3y

3.86

Median5y

3.95

-13.70

FCF Yield

Median3y

-6.65

Median5y

-6.62

Competitors Valuation Multiple

The average P/S ratio for PCVX's competitors is 43.16, providing a benchmark for relative valuation. Vaxcyte Inc Corp (PCVX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PCVX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PCVX in the past 1 year is driven by Unknown.